Canada Pension Plan Investment Board Buys New Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Canada Pension Plan Investment Board acquired a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 48,900 shares of the company's stock, valued at approximately $2,272,000. Canada Pension Plan Investment Board owned 0.08% of Twist Bioscience at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Van ECK Associates Corp boosted its holdings in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Twist Bioscience during the third quarter worth about $34,000. US Bancorp DE grew its holdings in Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the period. Beaird Harris Wealth Management LLC bought a new position in shares of Twist Bioscience during the third quarter valued at approximately $95,000. Finally, KBC Group NV lifted its holdings in shares of Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares during the last quarter.

Analyst Ratings Changes

TWST has been the topic of several recent research reports. Guggenheim set a $50.00 price target on Twist Bioscience in a research note on Friday, March 28th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $52.80.

Twist Bioscience Stock Performance

NASDAQ:TWST traded down $1.10 during trading hours on Tuesday, reaching $38.80. The company had a trading volume of 93,465 shares, compared to its average volume of 976,610. The firm's 50 day moving average price is $39.51 and its 200-day moving average price is $44.26. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -11.50 and a beta of 2.34. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 52 week low of $30.32 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience's revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.75) earnings per share. On average, analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Activity at Twist Bioscience

In other news, COO Patrick John Finn sold 2,845 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $140,400.75. Following the transaction, the chief operating officer now owns 269,199 shares of the company's stock, valued at $13,284,970.65. This trade represents a 1.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 5,200 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the sale, the chief executive officer now owns 667,318 shares in the company, valued at approximately $32,932,143.30. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,432 shares of company stock worth $1,038,170. 3.01% of the stock is owned by company insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.